Celgene, recently acquired by Bristol-Myers Squibb, raised prices on its top selling cancer drug, Revlimid. 

Announced January 3rd, the price of a 10 milligram dose of Revlimid will increase by 3.5%, totaling $719.82 per pill. Almost 10 years ago, at the end of 2007, the same pill at the same dosage cost $247.28. Celgene has continued year after year to routinely increase the price of its top selling drug. 

Cancer patients require many treatments of Revlimid per year. This price increase means patients will pay over $200,000 to receive cancer treatment that they need to stay alive. 

We need to hold Celgene responsible for their actions and bring to light their aggressive price increases. Sign this petition to tell Celgene and Bristol-Myers Squibb that they cannot unjustly raise prices on life saving drugs while needy cancer patients are suffering because they cannot afford treatment.